US NAT yield: Where are we after 2 years?

Transfusion Medicine

Volumn 12, Issue 4, 2002, Pages 243-253

  Stramer, S L ^a  

^a American Red Cross   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMATION; COST BENEFIT ANALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION PREVENTION; NONHUMAN; NUCLEIC ACID AMPLIFICATION; REVIEW; SCREENING TEST; UNITED STATES; VIRUS DETECTION; VIRUS INFECTION;

ANTIGENS, VIRAL; BLOOD DONORS; HEPACIVIRUS; HIV-1; HUMANS; INFECTION CONTROL; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; UNITED STATES;

EID: 0036674459     PISSN: 09587578     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3148.2002.00387.x     Document Type: Review

References (19)

1. Recent trends in seroprevalence and incidence of HIV-1/2, HCV, and HBV in US allogeneic blood donors
2. Recovery, persistence, and sequelae in HCV infection: A perspective on long-term outcome
3. NAT and blood safety: What is the paradigm?
4. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the inter organizational task force on nucleic acid amplification testing of blood donors
5. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study
6. The yield of nucleic acid testing (NAT) for HIV and HCV RNA in a population of US voluntary donors: Relationship to contemporary measures of incidence
7. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation
8. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection
9. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
10. Prolonged antibody-negative HCV viremia in a US blood donor with apparent HCV transmission to a recipient
11. Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting
12. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study
13. Why is there such difficulty in defining the natural history of hepatitis C?
14. Relationship of nucleic acid testing (NAT) results to HIV and HCV serology among donors: Relevance to counseling
15. NAT of the United States and Canadian blood supply
16. Rate of HIV antibody false positive Western blots (WB) and correlation with WB banding pattern
17. Sensitivity of HIV and HCV RNA by pooled genome amplification testing (GAT)
18. Replacement of HIV-1 p24 antigen screening with HIV-1 RNA nucleic acid testing (NAT) for whole blood donations
19. Hepatitis C genotypes: Current trends and future implications